Trends in melanoma in the elderly in Denmark, 1980–2012

Hoejberg, Lise; Gad, Dorte; Gyldenkerne, Niels; Bastholt, Lars

doi:10.3109/0284186x.2015.1114677

Cited by 6 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have shown a nearly 6-fold increase in incidence since 1989. This unfavorable trend among older men is in accordance with observations from other countries [17][18][19].…”

Section: Discussionsupporting

confidence: 92%

Melanoma in older patients: declining gap in survival between younger and older patients with melanoma

et al. 2019

View full text Add to dashboard Cite

Background: Older people have the highest incidence of melanoma and the population in most Western countries is ageing. We evaluated how the gap in incidence and survival between younger and older patients has developed during the past decades. Material and methods: All patients diagnosed with cutaneous melanoma between 1989 and 2015 (n ¼ 84,827) were identified from the Netherlands Cancer Registry. Elderly were defined as aged !70 years. Differences in patient and tumor characteristics were described, age-specific incidence rates were calculated, and relative survival (RS) and multivariable analyses estimating the Relative Excess Rate of dying (RER) were conducted Results: In older men, the melanoma age-standardized incidence increased from 18 to 103/100,000 person-years (py) between 1989 and 2015 and in older women from 23 to 70/100,000 py. In younger men and women, it increased from 8 to 21 and from 13 to 28/100,000 py, respectively. Median Breslow thickness declined from 1.8 to 1.1 mm and from 1.6 to 1.1 mm in older men and women (2003 versus 2015), and from 1.1 to 0.9 mm and 0.9 to 0.8 mm in younger men and women. In older men, 5-year RS increased from 67% (95% CI: 63%-72%) in 1989-1997 to 85% (95% CI: 83%-87%) in 2007-2015 and in older women from 81% (95% CI: 78%-85%) to 89% (95% CI: 87%-91%). In younger men and women, RS increased from 82% (95% CI: 81%-83%) to 90% (95% CI: 90%-91%) and from 92% (95% CI: 92%-93%) to 96% (95% CI: 95%-96%). After case-mix correction , older men and women no longer showed an improved survival over time (RER 2010(RER -2015(RER versus 2003(RER -2009 0.97; 95% CI: 0.81-1.16 and 0.95; 95% CI: 0.79-1.16). Whereas in younger men and women survival remained improved (RER 0.75; 95% CI: 0.67-0.83 and 0.77; 95%CI: 0.67-0.89). Conclusion:The gap in melanoma incidence between younger and older people is increasing due to a strong increase in incidence in older adults. Disparities in survival are declining, related to a narrowing gap in Breslow thickness.

show abstract

“…They have shown a nearly 6-fold increase in incidence since 1989. This unfavorable trend among older men is in accordance with observations from other countries [17][18][19].…”

Section: Discussionsupporting

confidence: 92%

Melanoma in older patients: declining gap in survival between younger and older patients with melanoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A few occurred in parts other than the skin, such as the eyes, esophagus, rectum, anus, and vagina. Melanoma is more common among middle-aged and elderly people, while patients under the age of 20 years old are rare [10]. This showes the prevalence of melanoma increases with age.…”

Section: Introduction Of Melanomamentioning

confidence: 85%

Applications of Nanomaterials for Theranostics of Melanoma

Jin

Cheah

et al. 2020

JNT

View full text Add to dashboard Cite

Melanoma is an aggressive form of skin cancer with a very high mortality rate. Early diagnosis of the disease, the utilization of more potent pharmacological agents, and more effective drug delivery systems are essential to achieve an optimal treatment plan. The applications of nanotechnology to improve therapeutic efficacy and early diagnosis for melanoma treatment have received great interest among researchers and clinicians. In this review, we summarize the recent progress of utilizing various nanomaterials for theranostics of melanoma. The key importance of using nanomaterials for theranostics of melanoma is to improve efficacy and reduce side effects, ensuring safe implementation in clinical use. As opposed to conventional in vitro diagnostic methods, in vivo medical imaging technologies have the advantages of being a type of non-invasive, real-time monitoring. Several common nanoparticles, including ultrasmall superparamagnetic iron oxide nanoparticles, silica nanoparticles, and carbon-based nanoparticles, have been applied to deliver chemotherapeutic agents for the theranostics of melanoma. The application of nanomaterials for theranostics in molecular imaging (MRI, PET, US, OI, etc.) plays an important role in targeting drug delivery of melanoma, by monitoring the distribution site of the molecular imaging probe and the therapeutic drug in the body in real-time. Hence, it is worthwhile to anticipate the approval of these nanomaterials for theranostics in molecular imaging by the US Food and Drug Administration in clinical trials.

show abstract